{"id":"recombinant-human-endostatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Hemorrhage"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201718","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endostatin is a naturally occurring endogenous angiogenesis inhibitor derived from collagen XVIII. The recombinant form binds to endothelial cells and inhibits their proliferation and migration, thereby suppressing the formation of new blood vessels that tumors require for growth and metastasis. By starving tumors of their blood supply, it restricts tumor expansion and progression.","oneSentence":"Recombinant human endostatin inhibits angiogenesis by blocking new blood vessel formation in tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:06.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06059261","phase":"PHASE2","title":"Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2026-02-09","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT06562673","phase":"PHASE1, PHASE2","title":"Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma","status":"COMPLETED","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-12-03","conditions":"Osteosarcoma, Bone Cancer","enrollment":10},{"nctId":"NCT03340194","phase":"","title":"Evaluation of Calcinosis in Systemic Sclerosis","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2017-11-30","conditions":"Systemic Sclerosis","enrollment":214},{"nctId":"NCT07154108","phase":"PHASE1","title":"Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-09-01","conditions":"Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)","enrollment":40},{"nctId":"NCT03086681","phase":"PHASE2","title":"Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma","status":"COMPLETED","sponsor":"Yong Zhang,MD","startDate":"2017-04-20","conditions":"Cervical Carcinoma","enrollment":120},{"nctId":"NCT06617936","phase":"PHASE2","title":"Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"Hua Zhang","startDate":"2024-08-27","conditions":"Unresectable Non-small Cell Lung Cancer","enrollment":36},{"nctId":"NCT07046312","phase":"","title":"Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2025-07","conditions":"Psoriatic Arthritis (PsA), Subclinical Right Ventricular Systolic Dysfunction","enrollment":60},{"nctId":"NCT06965231","phase":"PHASE2","title":"Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-01","conditions":"Melanoma of Skin, Acral Melanoma, Stage II Melanoma","enrollment":58},{"nctId":"NCT06747169","phase":"PHASE2","title":"Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Jian-Guo Zhou, MD, PhD","startDate":"2024-12-17","conditions":"Squamous Non-Small Cell Lung Cancer SqNSCLC","enrollment":32},{"nctId":"NCT04267978","phase":"PHASE2","title":"Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas","status":"RECRUITING","sponsor":"Beijing Sanbo Brain Hospital","startDate":"2020-02-13","conditions":"Glioblastoma, Recurrent, Lower Grade Glioma, Recurrent","enrollment":109},{"nctId":"NCT05278715","phase":"PHASE2","title":"Modified CV Regimen in Optic Pathway Glioma","status":"RECRUITING","sponsor":"Beijing Sanbo Brain Hospital","startDate":"2022-04-13","conditions":"Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma","enrollment":75},{"nctId":"NCT06618391","phase":"PHASE2","title":"Local Injection and Systemic Therapy in the Treatment of NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":84},{"nctId":"NCT06611826","phase":"PHASE2","title":"GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-09-30","conditions":"Nasopharynx Cancer","enrollment":41},{"nctId":"NCT06301828","phase":"PHASE2","title":"Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-02-21","conditions":"Gastrointestinal Neoplasms","enrollment":16},{"nctId":"NCT06279754","phase":"PHASE2","title":"Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xinxiang Medical College","startDate":"2024-02-18","conditions":"Locally Advanced Squamous Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03796364","phase":"PHASE2","title":"Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2018-09-01","conditions":"Radiation Pneumonitis, Endostatin","enrollment":126},{"nctId":"NCT06047860","phase":"PHASE2","title":"A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-06-16","conditions":"Advanced Solid Tumor, Refractory Tumor","enrollment":30},{"nctId":"NCT06041724","phase":"PHASE2","title":"Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-09-18","conditions":"Advanced Mucosal Melanoma","enrollment":46},{"nctId":"NCT04659421","phase":"PHASE2","title":"Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas","status":"COMPLETED","sponsor":"Beijing Sanbo Brain Hospital","startDate":"2020-11-03","conditions":"Low-grade Glioma, Pediatric Brain Tumor","enrollment":60},{"nctId":"NCT05879796","phase":"","title":"Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-05-16","conditions":"Cervical Cancer","enrollment":30},{"nctId":"NCT05782764","phase":"PHASE4","title":"A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom","status":"UNKNOWN","sponsor":"Xuzhou Medical University","startDate":"2023-06-01","conditions":"Lung Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT02350517","phase":"PHASE2","title":"Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2015-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT05574998","phase":"PHASE2","title":"First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2021-02-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":100},{"nctId":"NCT05551247","phase":"PHASE2","title":"Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-15","conditions":"Colorectal Neoplasms","enrollment":30},{"nctId":"NCT05529355","phase":"PHASE2","title":"Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Anhui Chest Hospital","startDate":"2022-09-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT05514275","phase":"PHASE2","title":"Radiotherapy Combined With Endostatin and Capecitabine for NPC","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT02749526","phase":"PHASE2","title":"Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial","status":"TERMINATED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-04","conditions":"Esophageal","enrollment":70},{"nctId":"NCT05448781","phase":"PHASE2","title":"Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC","status":"UNKNOWN","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2022-07-20","conditions":"Non Small Cell Lung Cancer, Endostatin","enrollment":38},{"nctId":"NCT05387681","phase":"PHASE2","title":"Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-05-30","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy","enrollment":35},{"nctId":"NCT05385185","phase":"PHASE2","title":"Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2022-05-01","conditions":"Leptomeningeal Metastasis, Immune Checkpoint Inhibitor, Endostatin","enrollment":20},{"nctId":"NCT05360979","phase":"PHASE2","title":"A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2022-05-15","conditions":"Non-small Cell Lung Cancer","enrollment":42},{"nctId":"NCT05298020","phase":"PHASE2","title":"Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2022-04-01","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT05243355","phase":"PHASE2","title":"Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-12-03","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":46},{"nctId":"NCT04942301","phase":"PHASE1","title":"PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-07-30","conditions":"Advanced or Metastatic NSCLC","enrollment":24},{"nctId":"NCT04699214","phase":"PHASE2","title":"Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment","status":"UNKNOWN","sponsor":"Yong Chen","startDate":"2020-09-01","conditions":"Other Disorders of Soft Tissues","enrollment":210},{"nctId":"NCT04633746","phase":"","title":"Plasma Endostatin Predicts Outcome of Septic AKI","status":"COMPLETED","sponsor":"Cairo University","startDate":"2019-01-20","conditions":"Acute Kidney Injury Due to Sepsis","enrollment":40},{"nctId":"NCT04613284","phase":"PHASE4","title":"Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2020-12-01","conditions":"Lung Cancer","enrollment":97},{"nctId":"NCT03989830","phase":"PHASE2","title":"Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors","status":"UNKNOWN","sponsor":"Sun Yan","startDate":"2019-07-29","conditions":"Head and Neck Neoplasms","enrollment":53},{"nctId":"NCT01846546","phase":"","title":"Cerebrospinal Fluid Endostatin/Collagen XVIII Concentrations in Patients With Severe Traumatic Brain Injury","status":"COMPLETED","sponsor":"Shanghai 6th People's Hospital","startDate":"2006-10","conditions":"Traumatic Brain Injury","enrollment":30},{"nctId":"NCT02157896","phase":"","title":"Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Shanghai 6th People's Hospital","startDate":"2013-05","conditions":"Acute Ischemic Stroke","enrollment":30},{"nctId":"NCT04413227","phase":"PHASE1","title":"A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2020-04-02","conditions":"NSCLC, Solid Tumor","enrollment":30},{"nctId":"NCT04356118","phase":"PHASE4","title":"Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis","status":"UNKNOWN","sponsor":"Hui Bu","startDate":"2020-06","conditions":"Leptomeningeal Metastasis","enrollment":30},{"nctId":"NCT04094909","phase":"PHASE2","title":"Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2020-02-06","conditions":"Staging IV NSCLC","enrollment":186},{"nctId":"NCT03121833","phase":"PHASE2","title":"Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-05-01","conditions":"Soft Tissue Sarcoma, Adult, Stage IIB","enrollment":52},{"nctId":"NCT00004872","phase":"PHASE1","title":"Endostatin in Treating Patients With Advanced Refractory Solid Tumors","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2000-03","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT04161352","phase":"","title":"Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-11-25","conditions":"Unresectable Stage III NSCLC","enrollment":500},{"nctId":"NCT04121975","phase":"PHASE2","title":"CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-08-01","conditions":"Cervical Cancer","enrollment":82},{"nctId":"NCT03932266","phase":"PHASE2","title":"Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2019-06","conditions":"Nasopharyngeal Carcinoma","enrollment":73},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT03917069","phase":"PHASE2","title":"Nab-PCE vs PC for MM After Failure of Anti-PD-1","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-03-23","conditions":"Advanced Melanoma","enrollment":145},{"nctId":"NCT03907098","phase":"PHASE2","title":"Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-06-30","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT03577392","phase":"PHASE2, PHASE3","title":"Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2018-07-01","conditions":"Quality of Life","enrollment":120},{"nctId":"NCT02902432","phase":"PHASE2","title":"A Trial of Endostar in Patients With Carcinoma of the Head and Neck","status":"UNKNOWN","sponsor":"China International Medical Foundation","startDate":"2016-06","conditions":"Nasopharyngeal Neoplasms","enrollment":24},{"nctId":"NCT03706703","phase":"PHASE2","title":"Rh-Endostatin (Endostar®) Continuous Intravenous Infusion","status":"UNKNOWN","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2018-10-01","conditions":"Lung Cancer","enrollment":50},{"nctId":"NCT03649945","phase":"PHASE2","title":"Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2018-11","conditions":"Esophageal Cancer","enrollment":186},{"nctId":"NCT03622827","phase":"PHASE2","title":"Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2018-07-31","conditions":"Uterine Cervical Neoplasms","enrollment":120},{"nctId":"NCT03614065","phase":"PHASE2","title":"Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2017-02-21","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT03588494","phase":"PHASE2, PHASE3","title":"Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of North Sichuan Medical College","startDate":"2018-08-01","conditions":"Quality of Life","enrollment":318},{"nctId":"NCT03206957","phase":"NA","title":"Correlation Between Optic Nerve Vessel Anomalies, Serum Angiogenic Factors and Renal Anomalies in Down Syndrome Children","status":"UNKNOWN","sponsor":"Queen Fabiola Children's University Hospital","startDate":"2017-11-30","conditions":"Down Syndrome","enrollment":200},{"nctId":"NCT03461185","phase":"PHASE2","title":"Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2018-05-01","conditions":"Non Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT03404037","phase":"","title":"Serum Endostatin Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2017-03-02","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease, Coronary Arteriosclerosis","enrollment":110},{"nctId":"NCT02590133","phase":"PHASE2","title":"A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC","status":"UNKNOWN","sponsor":"Yun-fei Xia","startDate":"2015-07","conditions":"Nasopharyngeal Carcinoma","enrollment":328},{"nctId":"NCT02489409","phase":"PHASE2","title":"Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Xinjiang Medical University","startDate":"2015-10","conditions":"Breast Neoplasms","enrollment":120},{"nctId":"NCT01733589","phase":"PHASE1, PHASE2","title":"Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2012-11","conditions":"Stage III Non-small-Cell Lung Cancer","enrollment":73},{"nctId":"NCT03208335","phase":"PHASE2","title":"Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2017-01-01","conditions":"Hepatocellular Carcinoma","enrollment":61},{"nctId":"NCT03123445","phase":"PHASE2","title":"Endostar First-line Treatment of Advanced NSCLC","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2017-04","conditions":"Non Small Cell Lung Cancer","enrollment":150},{"nctId":"NCT03117335","phase":"PHASE3","title":"Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.","startDate":"2011-11-10","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":560},{"nctId":"NCT01845675","phase":"PHASE2","title":"Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2013-04","conditions":"Advanced Well-differentiated Pancreatic Neuroendocrine Tumor","enrollment":14},{"nctId":"NCT01301443","phase":"PHASE1","title":"Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Oxford BioMedica","startDate":"2011-02","conditions":"Age Related Macular Degeneration","enrollment":21},{"nctId":"NCT03095079","phase":"PHASE2","title":"Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-10","conditions":"Melanoma","enrollment":70},{"nctId":"NCT02104323","phase":"PHASE2","title":"Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2014-01","conditions":"Vestibular Schwannoma, Neurofibromatosis Type 2","enrollment":20},{"nctId":"NCT03008109","phase":"PHASE3","title":"Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC","status":"UNKNOWN","sponsor":"Zaiwen Fan","startDate":"2017-02","conditions":"Advanced Cancer, Lung Cancer, Nonsmall Cell","enrollment":80},{"nctId":"NCT00668473","phase":"","title":"Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2007-05","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT02579564","phase":"PHASE3","title":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2016-10","conditions":"Malignant Hydrothorax, Non Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT02907710","phase":"PHASE3","title":"Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2016-10","conditions":"Nasopharyngeal Carcinoma","enrollment":300},{"nctId":"NCT02804646","phase":"PHASE4","title":"Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2016-06","conditions":"Adenocarcinoma of Lung","enrollment":100},{"nctId":"NCT02615106","phase":"PHASE2","title":"Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-11","conditions":"Neuroblastoma","enrollment":60},{"nctId":"NCT02748772","phase":"PHASE3","title":"Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical","status":"UNKNOWN","sponsor":"The First People's Hospital of Hefei","startDate":"2016-01","conditions":"Colorectal Neoplasms","enrollment":148},{"nctId":"NCT02745561","phase":"PHASE2","title":"Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.","status":"UNKNOWN","sponsor":"Hangzhou Cancer Hospital","startDate":"2016-01","conditions":"Esophageal Cancer, Endostatin","enrollment":22},{"nctId":"NCT02630264","phase":"PHASE3","title":"E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck","status":"UNKNOWN","sponsor":"Guangzhou Double Bioproducts Co., Ltd","startDate":"2013-06","conditions":"Head and Neck Neoplasms","enrollment":540},{"nctId":"NCT01430013","phase":"PHASE2","title":"Trial of Endostar Combined With CHOPT for T Cell Lymphoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2011-06","conditions":"T Cell Lymphoma","enrollment":30},{"nctId":"NCT02513342","phase":"PHASE4","title":"Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2015-03","conditions":"Advanced Lung Squamous Carcinoma","enrollment":400},{"nctId":"NCT02497118","phase":"PHASE4","title":"Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2010-08","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT00842491","phase":"PHASE2","title":"Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Peking University","startDate":"2008-11","conditions":"Advanced Gastric Cancer","enrollment":45},{"nctId":"NCT00900185","phase":"","title":"Study of a Polymorphism in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"","conditions":"Prostate Cancer","enrollment":750},{"nctId":"NCT02375022","phase":"PHASE2","title":"Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-03","conditions":"Lung Cancer","enrollment":10},{"nctId":"NCT02350361","phase":"PHASE2, PHASE3","title":"Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2014-01","conditions":"Lung Cancer","enrollment":60},{"nctId":"NCT01915134","phase":"PHASE3","title":"Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2013-08","conditions":"Effects of Chemotherapy, Stage IVC Nasopharyngeal Carcinoma","enrollment":362},{"nctId":"NCT02283476","phase":"PHASE3","title":"The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2014-11","conditions":"Lung Cancer","enrollment":200},{"nctId":"NCT02283489","phase":"PHASE2","title":"Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors","status":"UNKNOWN","sponsor":"Renmiao Zhang","startDate":"2014-10","conditions":"Head and Neck Neoplasms","enrollment":180},{"nctId":"NCT02159235","phase":"","title":"Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-09","conditions":"Ischemic Heart Disease, Coronary Artery Disease, Heavy Metal Toxicity","enrollment":200},{"nctId":"NCT01165515","phase":"","title":"Endostatin Serum Levels During Bicycle Stress Test","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2008-01","conditions":"Smoking, Cardiac Diseases","enrollment":240},{"nctId":"NCT01612286","phase":"PHASE2","title":"Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2012-05","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT02005120","phase":"PHASE2","title":"Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2013-12","conditions":"Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT02008422","phase":"PHASE3","title":"Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tang Xushan","startDate":"2013-08","conditions":"Gastric Cancer","enrollment":120},{"nctId":"NCT01347424","phase":"PHASE2","title":"Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2011-01","conditions":"Non Small Cell Lung Cancer, Nasopharyngeal Cancer, Liver Metastasis","enrollment":40},{"nctId":"NCT02001168","phase":"PHASE3","title":"Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB","status":"UNKNOWN","sponsor":"Xinjiang Medical University","startDate":"2013-10","conditions":"Non-small Cell Lung Cancer","enrollment":392},{"nctId":"NCT01529164","phase":"PHASE2","title":"Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-10","conditions":"Colorectal Cancer","enrollment":51},{"nctId":"NCT01812018","phase":"PHASE2","title":"Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Peng Yuan","startDate":"2012-11","conditions":"Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT01689558","phase":"PHASE2, PHASE3","title":"Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer","status":"UNKNOWN","sponsor":"Jin Feng","startDate":"2011-12","conditions":"1、Enough Cases, 2、Elekta Precise 1343 Digital Control Electron Linear Accelerator, Can Undertake Nasopharyngeal Carcinoma Specimens in the Materia，","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ADRENAL INSUFFICIENCY"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BLOOD ALBUMIN DECREASED"},{"count":1,"reaction":"BONE MARROW FAILURE"},{"count":1,"reaction":"CARDIOTOXICITY"},{"count":1,"reaction":"CHEST DISCOMFORT"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DECREASED APPETITE"}],"_approvalHistory":[],"publicationCount":328,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["endostar","rh-endostatin","Endostar","Evafolimab Injection","Endostatin"],"phase":"marketed","status":"active","brandName":"recombinant human endostatin","genericName":"recombinant human endostatin","companyName":"Peking University Cancer Hospital & Institute","companyId":"peking-university-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human endostatin is a hydrolytic enzyme that targets hyaluronic acid. It has been studied in clinical trials for various conditions, including non-small cell lung cancer, adenocarcinoma of the lung, type 2 diabetes, coronary artery disease, and coronary arteriosclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}